Identify the Risk of Acute Kidney Injury—Before It’s a Problem
The NephroCheck® Test was created for use alongside clinical evaluation of intensive care patients over 21 who have or have had acute cardiovascular and/or respiratory compromise in the past 24 hours. With results in just 20 minutes, the test is intended to assist the clinician in assessing the risk of moderate to severe acute kidney injury in the next 12 hours.
Identify, stratify and mitigate
the risk of acute kidney injury
Why is early identification of AKI important?
Dr. Peter McCullough discusses how early identification is fundamental for treating acute kidney injury. The NephroCheck® Test can help inform certain adjustments to critical care management.
Identifying AKI Biomarkers
The NephroCheck® Test is designed to detect the presence of two key biomarkers, allowing health care professionals to proactively assess the risk of acute kidney injury and potentially mitigate severe consequences.
A Renal “Alarm System”
The NephroCheck® Test produces a single numerical AKIRisk® Score in a reportable range of 0.04 to 10.0. Patients whose score exceeds 0.3 are considered to be at risk of developing acute kidney injury.
The NephroCheck® Test cutoff of > 0.3 was prospectively selected prior to validation studies to achieve*:
- High sensitivity
- Acceptable specificity
- High negative predictive value for AKIRisk® Score of ≤ 0.3
High sensitivity and negative predictive value ensure that:
- The majority of patients who will develop AKI test positive
- Few patients with a negative test result will be at risk of developing AKI
*Moderate to severe AKI in the next 12 hours.
Spotting at risk patients
The NephroCheck® AKIRisk® Score is reported as a single numerical result with a reportable range of 0.04 to 10.0. Results from Study A and B are not statistically different (p>0.05).
The NephroCheck® Test demonstrates significant discrimination between patients with and without AKI. There is no elevation of test results by chronic comorbidities or non-AKI acute conditions (relative to apparently healthy subjects).
More than 300 candidate biomarkers were studied and analyzed in more than 1,200 patients, including those with sepsis, shock, major surgery and trauma.3
More than 500 patients were prospectively enrolled across 29 sites to validate the NephroCheck® Test in two clinical studies. Patients had diverse reasons for ICU admission (surgery, sepsis, trauma) and had common comorbidities (including CKD, diabetes and heart disease).
A panel of expert nephrologists clinically adjudicated each patient as having or not having moderate or severe acute kidney injury while blinded to the NephroCheck® Test results.